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Study of malignant melanoma has dominated much of the activity in human 
cancer immunology (1-9).  This reflects the widespread belief that melanoma 
represents an immunogenic tumor in man. Although many indications exist 
that melanoma patients respond to their tumor by developing humoral and 
cellular immunity, critical evidence that these immune reactions are directed to 
melanoma-specific antigens is lacking. Thus, for instance, interpreting results 
of tests between serum or lymphoid cells of one patient and melanoma cells of 
another is frequently difficult, if not at times impossible, because of the un- 
known participation of alloantigens in  the reactions observed.  Also,  results 
restricted to  melanoma biopsy  material or primary cultures (in contrast to 
sequentially cultured melanoma cells)  commonly pose  questions  related to 
specificity and reproducibility, since the analysis is necessarily limited by the 
number and type of tests that can be performed. 
For  this  reason,  we  have  directed our  serological studies  of cell  surface 
antigens of melanoma to analyzing autologous reactions, i.e., serum and mela- 
noma cells from the same patient. The need for repeated tests in substantiating 
the specificity and reliability of positive or negative reactions requires the ready 
and continuing availability of target cells, and this has been met by establishing 
melanoma and accompanying autologous skin fibroblasts in cell culture. 
We have recently reported that 11 of 35 patients showed reactivity to autolo- 
gous melanoma by mixed hemadsorpti0n assays (10). Autologous fibroblasts 
from these same patients were negative. One patient (AU) showed a sufficiently 
high autologous reactivity to conduct an extensive absorption analysis of his 
serum. Tests on a range of malignant cell lines, melanoma and nonmelanoma, 
and  normal  cells,  autelogous  and  allogeneic,  revealed that  this  melanoma 
surface antigen was restricted to AU melanoma cells. 
The present report summarizes our experience with immune adherence (IA)  1 
assays for the detection of specific antibody to cell surface antigens of melanoma. 
*  This  work was  supported  by  grants from  the  Cancer  Research  Institute  Inc.,  the  Oliver  S. and 
Jennie R. Donaldson Charitable Trust,  and the National  Cancer  Institute  (P01 CA 19267 and CA 
08748). 
i  Abbreviations used in this paper: FBS, fetal  bovine serum; IA, immune adherence; VBM, 
Veronal buffer  medium. 
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Materials and Methods 
Tissue Culture.  For derivation of melanoma and other cell lines see Carey et al. (10) and Fogh 
and Trempe (11). Cells were cultured in Eagle's minimum essential medium supplemented with 2 
mM  glutamine, 1% nonessential  amino acids,  penicillin  i00 IU/ml, streptomycin 100 ~g/ml, and 
15% fetal  bovine serum (FBS). All cultures  were checked repeatedly for  mycoplasma, fungi,  and 
bacteria;  contaminated cultures  were discarded. 
Serology.  IA  assays were  performed  according  to  the  method of  Tachibana  and  Klein  modified 
for monolayer target cells (12). Cultured cells were harvested with 0.25% trypsin, washed,  and 
distributed to wells of Microtest II plates (no. 3040, Falcon Plastics, Oxnard, Calif.) so that each 
well received 500-1,500 cells. Plates were then incubated in a humidified 5% CO2 incubator until 
use. 
Serum titrations were prepared in Veronal buffer medium (VBM) with 5% FBS (VBM-FBS) on 
ice. Medium was decanted from the test plates, the wells washed three times with VBM-FBS, and 
0.05  ml  of each  serum  dilution was  added  per  well.  The  plates  were  then  incubated  at  the 
prescribed temperature  (4,  24,  or 37°C)  for 1 h,  washed three times with VBM-FBS,  and then 
washed with VBM.  Indicator cells (0.2%  [vol/vol] human O-type erythrocytes, and 1/60 diluted 
guinea pig serum as a source of complement in VBM) were added in 0.05-ml aliquots to each well. 
The plates were further incubated at 37°C  in a  humidified 5% COs incubator for 30 min. After 
incubation, the plates were agitated gently, washed once with VBM-FBS, and evaluated under a 
light microscope. 
Individual target cells were  scored as positive when 50% or more of the cell perimeter was 
surrounded by indicator cells. A well was considered positive only if at least 10% of the target cells 
met this criterion.  In each experiment,  control wells  incubated with VBM-FBS alone or  with 
human serum from normal pretested donors were included. The assay was considered evaluable 
only if these control tests showed less than 1% positive cells.  Titers refer to the highest serum 
dilution showing 10% positive target cells. 
Absorption tests were performed as previously described (10,  13,  14).  Serum was absorbed at 
two doubling dilutions below its end point (titer).  One aliquot of diluted serum remained un- 
absorbed, while other aliquots were mixed with cells to be tested. After preliminary experiments 
to determine optimal conditions, absorption was carried out on ice for 1 h with occasional shaking. 
For  qualitative  absorption,  0.15  ml diluted  serum  was  absorbed with  0.1  ml  packed  cells.  In 
quantitative absorption, diluted serum was absorbed with a  range of counted numbers of viable 
cells. Cell cultures were harvested for absorption tests with 0.05% EDTA or 0.25% trypsin, as tests 
showed that the melanoma antigens detected in IA assays were not destroyed by EDTA or trypsin 
at  these concentrations.  After  absorption,  the  cells were  removed  by  centrifugation,  and  the 
absorbed and unabsorbed sera were retested on the appropriate target cell. 
Results 
IA Assays on Autologous Melanoma Cells 
FREQUENCY  OF DEMONSTRABLE IA ANTIBODY.  Table I summarizes results of 
tests with sera from 18 melanoma patients on autologous melamona cell lines. 
To detect antibodies with differing affinity, incubation was carried out at 4, 24, 
or 37°C. Considering all tests together, autologous serum reactivity was demon- 
strable in 10 patients,  with serum titers ranging from 1/4 to 1/160. 
INFLUENCE  OF  TEMPERATURE  ON  IA  REACTIVITY,  On  the  basis  of frequency 
and strength of reaction (Table I), three categories can be defined: (a) optimal 
reactivity at 24 or 37°C: sera from patients AL, AO, AR, AU, AV and BD;  (b) 
optimal reactivity at 4°C: sera from patients AH and AX, and (c) no tempera- 
ture preference: sera from patients AP and AT. 
Fig.  1  illustrates  the  IA  reactivity  of sera  from  patients  BD  and  AH  at 
different incubation temperatures. BD sera reacted with autologous SK-MEL-37 
cells at 24 and 37°C, but not at 4°C. In contrast, AH sera were far more reactive 
with autologous melanoma SK-MEL-13  at 4°C than at higher temperatures. SHIKU,  TAKAHASHI,  OETTGEN,  AND  OLD  875 
TABLE  I 
Immune Adherence Assays for Autologous Serum Reactivity to Surface Antigens of Cultured 
Melanoma Cells 
Patient 
AD 
AH 
AI 
BO 
AL 
AO 
AP 
AQ 
AR 
AS 
AT 
AU 
AV 
AW 
AX 
BC 
BD 
BI 
Age  Sex 
45  F 
56  M 
49  M 
61  M 
50  M 
59  M 
67  F 
67  M 
43  F 
53  F 
52  F 
51  M 
19  M 
67  M 
33  F 
38  M 
65  M 
78  M 
No. of sera 
tested (months 
Designation  of  between coUec- 
melanoma cell 
tion of  first  and 
line 
last  serum spec- 
imens) 
SK-MEL-8§  6(18) 
SK-MEL-13§  16(24) 
SK-MEL-14§  5(9) 
SK-MEL-15  1(0) 
SK-MEL-19  5(12) 
SK-MEL-22  6(9) 
SK-MEL-23  6(6) 
SK-MEL-24§  15(5) 
SK-MEL-25]  4(3) 
SK-MEL-26§  6(4) 
SK-MEL-27§  12(6) 
SK-MEL-28§  9(14) 
SK-MEL-29§  4(2) 
SK-MEL-30  1(0) 
SK-MEL-31  6(5) 
SK-MEL-36  13(12) 
SK-MEL-37§  16(10) 
MeWo§  3(1) 
Frequency of IA reaction and titer of antibody 
4°C  * 
Pos./Test$  Titer 
0/3 
41/41  1/20-1/160 
0/3 
0/4 
0/4 
0/3 
3/3  1/4 
0/3 
0/6 
O/4 
4/5  1/4-1/16 
O/3 
1/3  1/4 
0/4 
7/7  1/4-1116 
0/5 
1/3  1/4 
0/3 
24°C 
Pos./Test  Titer 
0/3 
6/6  1/20-1/80 
0/3 
0/4 
0/4 
0/4 
1/3  1/4 
0/3 
4/7  1/4 
O/4 
5/6  1/4-1/32 
O/6 
9t10  i/4-I/16 
0/5 
0/3 
0/5 
29/29  1/8-1/96 
0/3 
37°C 
Pos./Test  Titer 
014 
17127  1120-I/80 
014 
013 
2/8  114 
4/6  I/4 
215  1/4 
0/3 
1/4  1/4 
0/4 
8/10  1/4-1/32 
6/12  1/4-1/32 
416  1/4-I/16 
0/4 
0/5 
0/4 
25/27  1/8-1/96 
0/3 
* Tem~ erature for incubation of  cells  with autologous sera in IA assay. 
* Number of  positive  tests/number  of  tests  performed. Each test  performed on all  available serum specimens from individual patients. 
§ Companion autologous skin fibroblast  lines  also established. 
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FIG.  1.  Influence of temperature  on IA reactivity.  (la,  left)  Reaction of BD serum on 
autologous SK-MEL-37 cells is optimal at 24 or 37°C; no reaction is seen at 4°C. (1 b, right) 
AH sera shows stronger reactivity with autologous SK-MEL-13 cells at 4°C than at higher 
temperatures. 
IA Assays on Autologous Skin Fibroblasts 
Skin fibroblasts  have been cultured  from 11 patients  in this study  (Table I). 
No autologous serum  reactivity  has been observed with  fibroblasts,  including 
repeated tests with the serum of patients  having antibody to autologous mela- 
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FIG.  2.  Reactivity of  sequential serum samples on autologous melanoma cells. (2a) Serum 
collected from patient AH over a period of  24 mo. (2 b) Serum collected from patient BD over 
a period of 10 mo. 
Analysis of AH and BD Sera: Definition  of Two Serologically Distinct Cell 
Surface Antigens of Melanoma 
In this series, sera from patients AH and BD were most strongly and consist- 
ently reactive against autologous melanoma cells and were therefore selected for 
detailed study. 
REACTIVITY  OF  SEQUENTIAL  SERUM  SAMPLES  ON  AUTOLQGOUS  MELANOMA 
CELLS.  Simultaneous titrations  of individual  serum specimens collected from 
patients AH and BD over a period of 1-2 yr are shown in Fig. 2. The reaction of 
AH sera remained essentially unchanged over a  24-mo period (Fig.  2a).  Sera 
from patient BD, however, showed a progressive fall in autologous melanoma 
reactivity (Fig.  2b). 
QUALITATIVE  ABSORPTION  ANALYSIS OF  AH  AND  BD  SERA.  Fig.  3 illustrates SHIKU,  TAKAHASHI,  OETTGEN,  AND  OLD 
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FIG. 3.  Qualitative absorption analysis of BD  and AH  sera.  Examples of individual 
absorption tests. (3a) Absorption of BD sera with autologous normal cells, autologous SK- 
MEL-37 cells, and allogeneic SK-MEL-13 cells. Only autologous SK-MEL-37 cells absorb IA 
reactivity. (3 b) Absorption of AH sera with autologous SK-MEL-13 cells, allogeneic mela- 
noma cell lir~es, and SK-RC-2 cells.  Autologous melanoma and two allogeneic melanoma 
cell lines, SK-MEL-23 and SK-MEL-27, absorb IA reactivity. 
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single absorption tests with AH and BD sera, and Tables II and III summarize 
the extensive series of qualitative absorptions which have been performed,with 
these sera.  The antigen defined by the reaction of BD sera on autologous SK- 
MEL-37 cells has been found on no other cell type, autologous,  allogeneic,  or 
xenogeneic (Fig.  3a  and Table II). The antigen  defined by the reaction of AH 
sera on autologous SK-MEL-13 cells has been detected on 4 of the 11 allogeneic 
melanoma cell lines, but on no other normal or neoplastic cell tested (Fig.  3 b 
and Table III). 
Thus,  absorption analysis has defined two serologically distinct cell surface 
antigens  of melanoma;  the  BD antigen  representing  an  individually  distinct 
(private) melanoma antigen  and the AH antigen representing  a  common (but 
not universal) melanoma antigen. 
ESTIMATION  OF AH ANTIGEN  EXPRESSION  BY AUTOLOGOtYS AND AH +  ALLOGENEIC 
MELANOMA  CELLS.  Fig. 4 illustrates quantitative  absorption tests with 4 AH  ÷ 
melanoma cell lines. As measured by absorption capacity per cell, SK-MEL-23 
cells and SK-MEL-29 cells have 10 times more AH antigen than autologous SK- 
MEL-13 cells; MeWo melanoma was found to have 10 times less. 
Further Characteristics of AH and BD Melanoma Antigens 
(a)  Quantitative  absorption  tests show that  AH and  BD antigens  are  not 
destroyed by 0.25%  trypsin  or 0.05%  EDTA;  (b) Viable melanoma  cells after 
controlled freezing in 10% dimethyl sulfoxide have sharply reduced levels of AH 
and  BD  antigens;  the  antigens  promptly  return  on  further  culture;  (c)  In 
contrast to the marked fluctuation in expression of AU melanoma antigen noted 
in  our  previous  study  (10),  AH  and  BD  antigens  show  little  fluctuation  in 
antigen expression from passage to passage or within a  single passage genera- 
tion;  (d)  Melanoma cells passaged in normal  human  serum rather  than  FBS 
continue to express AH and BD antigens,  as demonstrated by direct IA assays 
and absorption tests; and (e) Serum from 20 normal adults having no history of 
transfusion or pregnancy were negative for IA antibody to AH  ÷ cells and BD  + 
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TABLE  II 
Absorption of IA Reactivity from Serum of Patient BD Tested Against Autologous 
Melanoma Cells (SK-MEL-37) 
Positive  absorption  Negative absorption 
Autologoue  cultured  melanoma cells: 
SK-MEL-37 (BD) 
Autologous normal cells: 
Lymphoid cells 
Platelets 
Granulocytes 
Erythrgcytes 
Autologous cultured normal cells: 
BDFibroblasts 
Allogeneic normal cells: 
Pooled  buffy  coat  leukocytes 
A erythrocytes 
B erythrocytes 
AB erythrocytes 
O erythrocytes 
Xenogeneic cells  and serum: 
Sheep erythrocytes 
Guinea pig kidney 
Fetal bovine serum 
Oncornaviruses: 
SSV-1 
RD-114 
MuLV(AKR) 
Microorganisms: 
BCG 
Allogeneic cultured melanoma cells: 
SK-MEL-8 (AD) 
SK-MEL-13 (AH) 
SK-MEL-15 (BO) 
SK-MEL-19 (ALl 
SK-MEL-22 (AO) 
SK-MEL-23 (AP) 
SK-MEL-27 (AT) 
SK-MEL-28 (AU) 
SK~MEL-29  (AV) 
SK-MEL-30 (AW) 
SK-MEL-36 (BC) 
MeWo (BI) 
Allogeneic cultured nonmelanoma  cells: 
SK-RC-2 (renal  cell  ca) 
SK-RC-4 (renal  cell  ca) 
T-24 (bladder cal 
J-82 (bladder ca) 
ME-180 (cervical  ca) 
SK-LC-LL (lung  ca) 
SK-L7 (leukemia) 
Sal  Ill  (breast  ca) 
Allogeneic  cultured normal cells: 
AT fibroblasts 
Allogeneic  cultured  fetal cells: 
WI-38 (fetal lung fibroblasts) 
PHEL-6 (fetal lung fibroblasts) 
Discussion 
On the basis of this study  and our previous analysis  (10),  three distinctive 
antigens (or systems of antigens) can now be defined on the surface of melanoma 
cells. Two of these, AU and BD, belong to the category of individually unique 
antigens,  i.e., present only on a  single melanoma line.  The other, AH,  has a 
more widespread distribution, being detected on 5 out of 12 melanomas, and can 
be considered a common antigen shared by a class of melanomas. These methods 
are being applied to a growing series of melanomas and should, in time, provide 
a serological classification of the surface antigens of melanoma cells. Typing of 
new melanoma cell lines is presently being done by determining whether the 
cells specifically absorb reactivity from reference AU, BD, or AH sera, and the 
system  will be  extended  as  new melanoma  surface  antigens  are  recognized. 
Although this procedure of typing is both sensitive and accurate when dealing 
with a  single antigenic determinant,  it may well provide misleading informa- 
tion if our typing  system  is detecting  a  complex of determinants  on a  single 
molecule or a  system  of antigens  on different molecules.  Positive  absorption 
simply  signifies  that  the  antigens  being  detected  on the  target  cell  are  also 
present on the absorbing cell; if common as well as unique antigens are present 
on the target cell, then a common antigen on the absorbing cell (provided these 
cells lack the unique antigen) may well be missed. For this reason, absorption 
tests  should  be  supplemented  whenever  possible  by  direct  tests.  This  was 
possible in the case of AU typing serum since it lacked demonstrable alloanti- SHIKU,  TAKAHASHI,  OETTGEN,  AND  OLD  879 
TABLE  III 
Absorption of lA Reactivity from Serum of Patient AH Tested Against Autologous 
Melanoma  Cells (SK-MEL-13) 
Positive absorption  Negative absorption 
Autologous cultured melanoma cells: 
SK-MEL-13 (AH) 
AUogeneic cultured melanoma cells: 
SK-MEL-23 (AP) 
SK-MEL-27 (AT) 
SK-MEL-29 (AV) 
MeWo  (BI) 
Autologous normal cells: 
Lymphoid cells 
Platelets 
Granulocytes 
Erythrocytes 
Autologous cultured normal cells: 
AH fibroblasts 
Allogeneic  normal  cells:  (from  patients 
whose  cultured  melanoma  cells  absorb 
reactivity from AH serum) 
AT and AV: 
Lymphoid  cells 
Platelets 
Granulocytes 
Erythrocytes 
AP: 
Lymphoid  cells 
Allogeneic cultured normal cells: (from pa- 
tients whose cultured  melanoma cells  ab- 
sorb reactivity from AH serum) 
AT fibroblasts 
AV fibreblasts 
BI fibreblasts 
Allogeneic  normal cells: 
Pooled  buffy coat  leukocytas 
A erythrocytes 
B erythrsoytes 
AB erythrocytes 
O erythrocytes 
Xenogeneic cells  or serum: 
Sheep erythrocytes 
Guinea pig  kidney 
Fetal bovine serum 
Oncornavirusos: 
SSV-I 
RD-114 
MuLV(AKR) 
Microorganisms: 
BCG 
Corynebacterium parvurn 
Allogeneic  cultured melanoma cells: 
SK-MEL-8 (AD) 
SK-MEL-I5 (BO) 
SK-MEL-19 (AL) 
SK-MEL-22 (AO) 
SK-MEL-28 (AU) 
SK-MEL-30 (AW) 
SK-MEL-37 (BD) 
Allogeneic  cultured  nonmelanoma cells: 
SK-RC-2 (renal  cel  !  ca) 
SK-RC-4 (renal  cell  ca) 
T-24 (bladder ca) 
J-82 (bladder ca) 
SK-LC-LL (lung ca) 
SK-LU1 (lung ca) 
Sal HI (breast  ca) 
AIAb (breast  ca) 
ME  180 (cervical  ca) 
HeLa (cervical  ca) 
SK-OV-3 (ovarian ca) 
HT-29 (colon  ca) 
Allogeneic  cultured normal cells: 
AU fibroblasts 
FB fibmblasts 
FB normal kidney cells 
Allogeneic cultured fetal cells: 
WI-38 (fetal lung fibroblasts) 
PHEL-6 (fetal lung fibroblasts) 
bodies (10). Tests on 22 allogeneic melanoma cell lines, including those derived 
from  patients  BD  and  AH,  were  negative,  confirming  the  conclusion  from 
absorption tests that AU antigen was restricted to a single melanoma cell line. 
In  cases  where  typing  sera  contain  alloantibody,  it  should  theoretically  be 
possible to render these sera suitable for direct tests on particular melanoma cell 
lines by prior absorption with corresponding autologous leukocytes, platelets, or 
fibroblasts.  Even under these circumstances,  however, caution should be exer- 
cised  in concluding that  a  positive  reaction  signifies  common antigens,  since 
melanomas may possess differentiation alloantigens not present on other autol- 
ogous cell types.  Undoubtedly, the biochemical characterization  of these mela- 
noma antigens,  which  is  now feasible  with  the  serological  reagents  that  are 
available,  will  define  in  more  precise  terms  what  we  mean  by  individually 
unique (private) versus common antigens, just as comparable studies of histo- 
compatibility  antigens  have  clarified  these  issues.  Equally  important,  such 
studies may give insight into the genetic origin of these specific surface compo- 
nents of melanoma cells. 880  ANTIGENS  OF  MALIGNANT  MELANOMA 
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FIG. 4.  Quantitative absorption  test to compare expression  of AH antigen by four AH  ÷ 
melanoma cell lines. Absorption system (see text); aliquots of 1/5 diluted AH sera absorbed 
with counted numbers of autologous  and allogeneic melanoma cells and tested on autolo- 
gous SK-MEL-13 cells. Dotted line represents reactivity of unabsorbed diluted AH serum. 
SK-MEL-13 cells, SK-MEL-23 cells, and SKoMEL-29 cells are of similar size (0.1 ml packed 
cells = 2 × 107 cells); MeWo cells are smaller (0.1 ml packed cells = 4 × 107 cells). On the 
basis of absorption capacity per cell,  allogeneic  SK-MEL-23 cells  and SK-MEL-29 cells 
express approximately 10 times more AH antigen than autologous SK-MEL-13 cells. MeWo 
cells absorb 10 times less. 
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As our  serological  analysis of melanoma surface  antigens  proceeds,  it  will 
become possible to determine whether the serological findings relate to clinical 
parameters, e.g., correlation of clinical status and course with presence and titer 
of antibody, temperature characteristics of antibody, and presence of common or 
private melanoma antigens.  Although it is tempting to see if such associations 
could be made at this point, we feel that it would be misleading to do so until the 
serological  classification  is  further  advanced.  If human  cancer  serology  is  to 
aspire to the accuracy, reproducibility, and usefulness of tissue typing and blood 
bank serology, the antigenic systems of human cancer must first be established 
with the precision that characterizes HLA serology and blood typing. When this 
has  been  accomplished,  the  application  of immunological  approaches  to  the 
study and therapy of human cancer will have been greatly facilitated. 
Summary 
Immune adherence assays revealed that 10 out of 18 melanoma patients had 
demonstrable  antibody  to  surface  antigens  of autologous  cultured  melanoma 
cells, with serum titers ranging from 1/4 to 1/160. Autologous fibroblasts showed 
no reactions with these sera. Antibody from individual patients showed repro- 
ducible  temperature  preference  for  maximal  reactivity.  Two  new  melanoma 
antigenic  systems were defined in this study.  The first,  BD,  was restricted  to 
autologous melanoma and could not be demonstrated in absorption tests on 12 
allogeneic melanoma cell lines. The other, AH, was found on 5 of 12 melanomas SH1KU~  TAKAHASHI~  OETTGEN~  AND  OLD  881 
and represents a class of shared melanoma surface antigens. Neither BD nor AH 
antigen  was found on normal cells from autologous,  allogeneic,  or xenogeneic 
sources or on any nonmelanoma tumor cell line.  Methods are now available to 
develop  a  comprehensive  serological  classification  of the  surface  antigens  of 
melanoma. 
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